@article{931b91df1ede4368b36fde6c66688f99,
title = "Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes",
abstract = "In this report, we looked at whether repeat prostate-specific antigen (PSA) measurements, or PSA kinetics, improve prediction of biopsy outcomes in men using active surveillance to manage localized prostate cancer. We found that in a large multicenter active surveillance cohort, PSA kinetics improves the prediction of surveillance biopsy outcome.",
keywords = "Active surveillance, Kinetics, Outcomes, Prostate cancer, Prostate-specific antigen",
author = "Cooperberg, {Matthew R.} and Brooks, {James D.} and Faino, {Anna V.} and Newcomb, {Lisa F.} and Kearns, {James T.} and Carroll, {Peter R.} and Atreya Dash and Ruth Etzioni and Fabrizio, {Michael D.} and Gleave, {Martin E.} and Morgan, {Todd M.} and Nelson, {Peter S.} and Thompson, {Ian M.} and Wagner, {Andrew A.} and Lin, {Daniel W.} and Yingye Zheng",
note = "Funding Information: We found that a sophisticated mathematical approach to measuring PSAk, as reflected in the novel PSAk parameter, can improve prediction of outcomes for men on surveillance for prostate cancer and that PSA may need to be measured no more often than semiannually. Obviously, PSA should never be interpreted in a vacuum, and we did not identify a PSAk threshold that should always indicate treatment. These results, which must be validated in other surveillance cohorts, suggest that PSAk or similar assessments of kinetics should be considered in future multivariable models of AS outcomes. Author contributions: Matthew R. Cooperberg had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Cooperberg, Brooks, Lin, Zheng. Acquisition of data: Newcomb, Carroll, Dash, Fabrizio, Gleave, Thompson, Wagner, Lin. Analysis and interpretation of data: Faino, Zheng, Cooperberg, Brooks, Lin, Newcomb, Kearns. Drafting of the manuscript: Cooperberg, Brooks, Lin, Zheng, Newcomb, Faino. Critical revision of the manuscript for important intellectual content: Cooperberg, Brooks, Faino, Newcomb, Kearns, Carroll, Dash, Etzioni, Fabrizio, Gleave, Nelson, Thompson, Wagner, Lin, Zheng. Statistical analysis: Faino, Zheng. Obtaining funding: Cooperberg, Lin, Nelson. Administrative, technical, or material support: None. Supervision: None. Other: None. Financial disclosures: Matthew R. Cooperberg certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None. Funding/Support and role of the sponsor: Department of Defense Prostate Cancer Research Program (grants W81XWH1110489 and W81XWH1410595); Canary Foundation. Appendix A ",
year = "2018",
month = aug,
doi = "10.1016/j.eururo.2018.01.017",
language = "English (US)",
volume = "74",
pages = "211--217",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "2",
}